AstraZeneca Pharmaceuticals LP
950 Wind River Lane
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
Please click here for clinical trial information.
Please click here for AstraZeneca job opportunities.
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
Tweets by AstraZeneca
What Science Can Do
2042 articles with AstraZeneca Pharmaceuticals LP
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
3/18/2019The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
The two companies will focus on utilizing the microbiome, all the bacteria, viruses and fungi in the body, to improve cancer immunotherapy.
Alex Trebek, 78, host of TV game show “Jeopardy” announced yesterday that he had been diagnosed with stage 4 pancreatic cancer.
U.S. Senator Chuck Grassley (R-Iowa) set the tone early, mentioning his constituents rationing drugs because of high prices or “leaving their prescription on the pharmacy counter because it costs too much,” but acknowledging that innovations “take time and money.”
The drug is being developed and commercialized jointly by AstraZeneca and Merck. It has already been approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
Investors are showing some love to AstraZeneca on this Valentine’s Day after the company posted strong year-end results. Shares of AstraZeneca are up more than 6 percent in premarket trading on the strength of the company’s financial results.
2/13/2019The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party instituti...
1/29/2019The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc...
Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares
Swedish Orphan Biovitrum AB announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
1/18/2019Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
Luye Pharma Reaches Strategic Partnership with AstraZeneca, Strengthens Commitment to Cardiovascular Therapeutic Field
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.